touchPODCAST

MDT perspectives on biologic treatment selection in severe type 2 asthma

touchMDT for touchIMMUNOLOGY

Listen to key experts from a multidisciplinary team explore the use of endotyping and biomarkers in guiding biologic treatment selection for patients with severe type 2 asthma.

The multidisciplinary team 

• Allergist: Professor Ioana Agache, Romania
• Primary care physician: Professor Barbara Yawn, USA
• Pulmonologist: Professor Alberto Papi, Italy

This touchPODCAST is for HCPs only.

This activity is funded by an unrestricted independent medical education grant from Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme. This activity is jointly provided by USF Health and touchIME.

For further information visit our website: https://touchimmunologyime.org/strategies-for-the-management-of-severe-type-2-asthma-expert-insight-into-optimizing-care//

Advancing the treatment of MDS and AML: An update from ASH 2021

touchCONGRESS for touchONCOLOGY

Listen to Prof. Pierre Fenaux (France) review key data presented at ASH 2021 on emerging treatments for patients with higher-risk MDS and newly diagnosed AML and offer his insights on their potential impact on future clinical practice, alongside those from Dr Esther Oliva (Italy) and Prof. Andrew Wei (Australia).

OVERVIEW

• Data review with Prof. Fenaux (0:00)
• Expert interviews with Prof. Fenaux, Dr Oliva and Prof. Wei, answering the questions below

INTERVIEW QUESTIONS

1. What have we learned about targeting specific mutations in MDS and how will this impact the treatment landscape in the future? (30:30)
2. Based on presentations at ASH 2021, what other emerging treatments for higher-risk MDS are likely to influence clinical practice? (36:13)
3. What have we learned about targeting specific mutations in patients with newly diagnosed AML not eligible for intensive chemotherapy, and how will this impact the treatment landscape in the future? (43:15)
4. Based on presentations at ASH 2021, what other emerging treatments for patients with newly diagnosed AML unfit for intensive chemotherapy are likely to influence clinical practice? (50:06)
5. What do presentations at ASH 2021 tell us about treatment personalization for patients with higher-risk MDS and newly diagnosed AML unfit for intensive chemotherapy? (55:13)

This touchPODCAST is for HCPs only. 

This activity is funded by an independent medical education grant from Novartis. This activity is provided by touchIME.

For further information visit our website: https://touchoncology.com/education/mds-aml-ash-2021/

Immunotherapy for recurrent or metastatic head and neck squamous cell carcinoma

touchPANEL DISCUSSION for touchONCOLOGY

Listen to three experts as they explore key clinical considerations when using immune checkpoint inhibitors to treat recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). The discussion includes the current role of immune checkpoint inhibitors, factors that may inform treatment decisions and approaches for managing side effects associated with immune checkpoint inhibitors.

The experts

• Prof. Kevin Harrington – The Institute of Cancer Research, London, UK
• Prof. Barbara Burtness – Yale Cancer Center, New Haven, CT, USA
• Prof. Jean-Pascal Machiels – Department of Medical Oncology, Cliniques Universitaire St-Luc, Brussels, Belgium

This touchPODCAST is for HCPs only.

This activity is funded by an unrestricted independent medical education grant from Merck and Co., Inc. This activity is jointly provided by USF Health and touchIME.

For further information visit our website: https://touchoncologyime.org/immunotherapy-rmhnscc-practical-considerations/

HPV infection and TGF-β: Translating the science into treatments for HPV-associated cancers

touchEXPERT OPINIONS for touchONCOLOGY

Listen to leading experts consider the current treatment options and unmet needs for patients with HPV-associated cancers, the link between HPV and TGF-β, and how this is driving the development of new treatments.

The experts

• Dr Judith Michels, Institut Gustave Roussy, Villejuif, France
• Dr Andrew Sikora, MD Anderson Cancer Center, Houston, TX, USA
• Dr Krishnansu Tewari, University of California, Irvine, CA, USA

This touchPODCAST is for HCPs only.

This activity is funded by an unrestricted independent medical education grant from GSK and Merck KGaA, Darmstadt, Germany. This activity is jointly provided by USF Health and touchIME. 

For further information visit our website:
https://touchoncologyime.org/hpv-associated-cancers/?_ga=2.151091262.621073815.1642410762-2024672127.1626340027

MDT and patient perspectives on the long-term management of patients with severe type 2 asthma

touchMDT for touchIMMUNOLOGY

Listen to key experts from a multidisciplinary team, and a patient with severe asthma, discuss evidence-based guidance for the long-term management of patients with severe type 2 asthma. 

The multidisciplinary team 

• Pulmonologist: Professor Alberto Papi, Italy
• Allergist: Professor Ioana Agache, Romania
• Primary care physician: Professor Barbara Yawn, USA
• Patient: Ms JoJo O’Neal, USA

This touchPODCAST is for HCPs only.

This activity is funded by an unrestricted independent medical education grant from Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme. This activity jointly provided by USF Health and touchIME.

For further information visit: https://touchimmunologyime.org/strategies-for-the-management-of-severe-type-2-asthma-expert-insight-into-optimizing-care//

Immune checkpoint inhibitors in prostate cancer: Current and future practice

touchEXPERT OPINIONS for touchONCOLOGY

Listen to leading experts consider the current role of immune checkpoint inhibitors in prostate cancer and possible future directions.

The experts

• Prof. Karim Fizazi - Gustave Roussy, Villejuif, France
• Dr Sandy Srinivas - Stanford University, Stanford, CA, USA
• Prof. Johann de Bono - The Institute of Cancer Research, London, UK

This touchPODCAST is for HCPs only.

This activity is funded by an unrestricted independent medical education grant from Merck Sharp & Dohme Corp. This activity is jointly provided by USF Health and touchIME.

For further information visit our website: https://touchoncologyime.org/icis-prostate-cancer/

Targeting the pathobiology of ESCC: Potential impact of immunotherapy on clinical practice

touchEXPERT OPINIONS for touchONCOLOGY

Listen to leading experts provide an update on the underlying pathobiology of esophageal squamous cell carcinoma, and review current and emerging therapies.

The experts

• Prof. Ken Kato, National Cancer Center Hospital, Tokyo, Japan
• Dr Jean-Phillipe Metges, University Hospital of Brest, Brest, France 

This touchPODCAST is for HCPs only.

This activity is funded by an independent medical education grant from Novartis. This activity is provided by touchIME.

For further information visit our website: https://touchoncologyime.org/targeting-pathobio-of-ESCC-and-emerging-impact-of-IO

Experts discuss how endotyping and biomarkers can help to guide treatment selection in severe type 2 asthma - touchIMMUNOLOGY

touchPANEL DISCUSSION for touchIMMUNOLOGY

Listen to leading experts discuss the serious consequences of severe type 2 asthma, how endotyping and biomarkers can help guide treatment selection in such patients, and how recent data and clinical guidelines can inform the long-term management of patients with severe type 2 asthma.

The experts

• Dr Katharine Woessner, Scripps Clinic Medical Group, San Diego, CA, USA
• Prof. Louis-Philippe Boulet, Laval University, Quebec City, Canada 
• Prof. Arnaud Bourdin, Arnaud de Villeneuve Hospital, Montpellier, France

This touchPODCAST is for HCPs only.

This activity is funded by an unrestricted independent educational grant from Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme. This activity is jointly provided by USF Health and touchIME.

For further information visit our website:  https://touchimmunologyime.org/endotypes-for-treatment-selection-in-severe-T2-asthma/

Experts discuss how endotyping and biomarkers can help to guide treatment selection in severe type 2 asthma - touchRESPIRATORY

touchPANEL DISCUSSION for touchRESPIRATORY

Listen to leading experts discuss the serious consequences of severe type 2 asthma, how endotyping and biomarkers can help guide treatment selection in such patients, and how recent data and clinical guidelines can inform the long-term management of patients with severe type 2 asthma.

The experts

• Dr Katharine Woessner, Scripps Clinic Medical Group, San Diego, CA, USA
• Prof. Louis-Philippe Boulet, Laval University, Quebec City, Canada 
• Prof. Arnaud Bourdin, Arnaud de Villeneuve Hospital, Montpellier, France

This touchPODCAST is for HCPs only.

This activity is funded by an unrestricted independent educational grant from Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme. This activity is jointly provided by USF Health and touchIME.

For further information visit our website:  https://touchrespiratoryime.org/endotypes-for-treatment-selection-in-severe-T2-asthma/

Improving outcomes for patients with NTM-LD

touchEXPERT OPINIONS for touchINFECTIOUS DISEASES

Listen to leading experts consider how to optimize the diagnosis of nontuberculous mycobacterial lung disease (NTM-LD) and how to manage it considering the latest treatment guidelines.

The experts

• Dr Juzar Ali, LSU Health Sciences Center, New Orleans, LA, USA
• Dr Doreen Addrizzo-Harris, NYU Grossman School of Medicine, New York, NY, USA
• Dr Kevin Winthrop, Oregon Health & Science University, Portland, OR, USA

This touchPODCAST is for HCPs only.

This activity is funded by an unrestricted independent medical education grant from Insmed. This activity is jointly provided by USF Health and touchIME. 

For further information visit our website: touchinfectiousdiseasesime.org/guideline-based-strategies-ntm-ld